SCHEMBL12433680

SCHEMBL12433680

CCCCNc1cccc2c1OCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MGAM O43451 1/20 0.37
AMY1A P0DUB6 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
TLR8 Q9NR97 1/20 0.36
NR4A2 P43354 1/20 0.36
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18893494 0.90 TTBK1 (0.45) TTBK1TTBK2LMNAHPGDPOLB
SCHEMBL9258744 0.83 KDM4E (0.45) TTBK1TTBK2LMNAHPGDPOLB
SCHEMBL3657085 0.81 KDM4E (0.46) TTBK1TTBK2LMNAHPGDPOLB
SCHEMBL507057 0.74 TTBK1 (0.47) TTBK1TTBK2LMNAHPGDPOLB
SCHEMBL25891383 0.74 IDH1 (0.41) LMNAPOLBMAPK1ALDH1A1CYP1A2
SCHEMBL23891754 0.73 MTNR1A (0.48) ALDH1A1MGAMAMY1AGAASI
SCHEMBL9222529 0.73 SMN1; SMN2 (0.53) LMNAHPGDPOLBMAPK1KDM4E
SCHEMBL11754066 0.72 ALDH1A1 (0.53) TTBK1TTBK2LMNAHPGDPOLB
SCHEMBL309485 0.71 TLR8 (0.53) POLBKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL9440359 0.71 MTNR1A (0.48) MTNR1AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
EP-2532652-B1 THERAPEUTIC AGENT FOR HEPATITIS C UNIV KAGOSHIMA (JP) 2014-11-12 EP disclosed
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C ONCOLYS BIOPHARMA, INC. (JP) 2012-12-13 US disclosed
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C ONCOLYS BIOPHARMA, INC. (JP) 2012-12-13 US disclosed
EP-2532652-A1 THERAPEUTIC AGENT FOR HEPATITIS C Kagoshima University (JP) 2012-12-12 EP disclosed
WO-2011093483-A1 THERAPEUTIC AGENT FOR HEPATITIS C 国立大学法人鹿児島大学 (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, SARS1 TTBK1 4369/4885TTBK2 3336/4885LMNA 2524/4885
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C HAVCR2, SLC10A1, FABP1 TTBK1 2969/4885TTBK2 3588/4885LMNA 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.